Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetricâ„¢ technology. Zymeworks has entered into separate agreements with BeiGene, ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetricâ„¢ technology. Zymeworks has entered into separate agreements with BeiGene, ...
The bispecific antibody is currently under FDA priority review for biliary tract cancer, with a target action date of Nov. 29. If approved, Zymeworks (NASDAQ:ZYME) is set to receive milestone ...
Zymeworks, Inc. is a biopharmaceutical company ... Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor ...
is an important advance and offers the first and only dual HER2-targeted bispecific antibody and chemotherapy-free treatment for patients living with BTC. In late 2022, Zymeworks entered into a ...
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with ...
And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
VANCOUVER, British Columbia, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq ... the late-stage HER2-targeting bispecific antibody to the FDA and we eagerly anticipate the potential ...
Jazz Pharma has lost little time in deciding to buy into Zymeworks' HER2-directed bispecific antibody zanidatamab, paying $325 million upfront for rights to the drug just weeks after taking an ...